Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Csl Ltd ADR (OP: CSLLY )

88.94 -1.16 (-1.29%)
Streaming Delayed Price Updated: 10:19 AM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,848
Open 89.25
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 90.10
Today's Range 88.88 - 89.84
52wk Range 71.51 - 103.97
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia 
Via MarketBeat
Exposures Product Safety

Performance

YTD
-8.18%
-8.18%
1 Month
-3.71%
-3.71%
3 Month
-7.38%
-7.38%
6 Month
+19.61%
+19.61%
1 Year
-11.56%
-11.56%

More News

Read More
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
Arcturus Shares Jump After Collaboration With CSL For mRNA-Based Vaccines
Via Benzinga
CSL Posts Encouraging Data From Garadacimab In Severe Swelling Attacks
Via Benzinga
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
From Arcturus Therapeutics
Via Business Wire
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
From Arcturus Therapeutics
Via Business Wire
Arcturus Therapeutics' Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside
Via Benzinga
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
Via Investor's Business Daily
Exposures Product Safety
Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
From Cara Therapeutics, Inc.
Via GlobeNewswire
OTC Markets Group Welcomes CSL Limited to OTCQX
From OTC Markets
Via GlobeNewswire
5 Diverse Medical Stocks To Buy For 2023 And Beyond
Via Talk Markets
Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories
Via Benzinga
Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case'
Via Benzinga
Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
From Amarin Corporation plc
Via GlobeNewswire
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
Via Benzinga
Why CSL Ltd Stock Could Be Worth a Look
Via MarketBeat
Exposures Product Safety
FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults
Via Benzinga
Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today?
Via InvestorPlace
Travere, CSL's Sparsentan Application Is Under European Review For Rare Kidney Disorder
Via Benzinga
Finalization of Vifor Pharma acquisition
From Vifor Pharma AG
Via Business Wire
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product
Via Benzinga
CSL Seals $11.7B Buyout Deal Of Vifor Pharma, Probably the Largest Healthcare Deal In 2021
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.